Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.
Rie
R
Yamazaki
Yoshinobu
Y
Aisa
Takehiko
T
Mori
Osamu
O
Iketani
Yasuo
Y
Ikeda
Shinichiro
S
Okamoto
D000328:Adult; D001549:Benzamides; D003106:Colon / Q000378:metabolism / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000068877:Imatinib Mesylate; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000601:surgery; D007583:Jejunum / Q000378:metabolism / Q000601:surgery; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D011743:Pyrimidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate